Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Echinobase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
Echinobase
ECB-ART-55003
Adv Ther 2026 May 09; doi: 10.1007/s12325-026-03622-3.
Show Gene links Show Anatomy links

Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study.

Tursi A, Pasta A, Elisei W, Barberio B, Mocci G, Savarino EV, de Barba C, Maconi G, Cataletti G, Scaldaferri F, Napolitano D, Costa F, Ceccarelli L, Marzo M, Monterubbianesi R, di Fonzo M, Lombardi G, Patturelli M, Ribaldone DG, Bertani L, Rodino' S, Sebkova L, Bodini G, Pranzo G, Serio M, Scarcelli A, Luppino I, Ferronato A, Spagnuolo R, Luzza F, Morano D, Gravina AG, Pellegrino R, Vespere G, Sedda S, Allegretta L, Fanigliulo L, Grossi L, Cortellini F, Forti G, Neve V, Piergallini S, Scarozza P, Bevevino G, Iacopini F, Capone P, Gaiani F, Kayali S, Mucherino C, D'antonio E, D'ascoli B, Colucci R, Bachetti F, Giorgetti GM, Clemente V, Pagnini C, Cuomo A, Donnarumma L, Onidi FM, Satta PU, Picchio M, Papa A, Italian Network for Inflammatory Bowel Diseases (IN-IBD).


???displayArticle.abstract???
INTRODUCTION: Tofacitinib, filgotinib, and upadacitinib are Janus kinase inhibitors (JAKis) available for ulcerative colitis (UC) refractory or intolerant to at least one advanced therapy; their comparative effectiveness in clinical practice remains uncertain. METHODS: We conducted a multicenter retrospective study including adult UC patients initiating tofacitinib, filgotinib, or upadacitinib (September 2020-June 2025). Clinical remission (partial Mayo score ≤ 1), steroid-free clinical remission, biochemical remission, and endoscopic remission (Mayo endoscopic score = 0) were assessed at predefined time-points. Baseline differences were controlled using inverse probability of treatment weighting (IPTW), and time-to-event and longitudinal analyses were performed. RESULTS: After IPTW, the pseudo-population included 627 patients (tofacitinib = 179, filgotinib = 138, upadacitinib = 310). In the weighted cohort, clinical remission probabilities at weeks 8, 24, and 52 were 17.5%, 40.7%, and 61.3% with upadacitinib, 11.8%, 33.8%, and 54.6% with tofacitinib, and 6.7%, 29.0%, and 52.0% with filgotinib, respectively; p < 0.001 at weeks 8 and 24; p = 0.040 at week 52. Steroid-free clinical remission showed a similar gradient (14.2%, 39.2%, and 59.8% with upadacitinib; 9.2%, 31.2%, and 50.8% with tofacitinib; 4.4%, 27.6%, and 49.8% with filgotinib, respectively; all p < 0.001. Biochemical remission was also achieved more frequently with upadacitinib at weeks 8 and 16, although differences between treatments were no longer significant during maintenance. At week 52, endoscopic remission was 18.8% with tofacitinib, 36.6% with upadacitinib, and 19.5% with filgotinib (p = 0.039). Overall adverse events, particularly infections and herpes zoster, were more frequent with tofacitinib, whereas filgotinib had fewer non-serious events; serious adverse events and colectomy risk were uncommon and similar across groups. CONCLUSIONS: All three JAKis were effective, but upadacitinib yielded the highest remission rates, while tofacitinib and filgotinib differed mainly in safety, supporting individualized drug positioning according to efficacy needs and patient-specific risks.

???displayArticle.pubmedLink??? 42105145
???displayArticle.link??? Adv Ther